CM
MDGL icon

Caption Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Caption Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.8M Buy
+22,500
New +$10.7M 0.07% 295
2025
Q1 		– Sell
-81,100
Closed -$25M – 1836
2024
Q4 		$25M Buy
81,100
+71,100
+711% +$20M 0.24% 62
2024
Q3 		$2.12M Buy
+10,000
New +$2.56M 0.03% 535
2023
Q4 		– Sell
-100,400
Closed -$14.7M – 1537
2023
Q3 		$14.7M Buy
100,400
+80,400
+402% +$15.1M 0.23% 100
2023
Q2 		$4.62M Buy
+20,000
New +$5.42M 0.08% 306
2023
Q1 		– Sell
-85,300
Closed -$24.8M – 1358
2022
Q4 		$24.8M Buy
+85,300
New +$8.34M 0.39% 51
2022
Q2 		– Sell
-25,000
Closed -$2.45M – 1675
2022
Q1 		$2.45M Buy
+25,000
New +$2.11M 0.03% 677
2021
Q1 		– Sell
-10,000
Closed -$1.11M – 1266
2020
Q4 		$1.11M Hold
10,000
– – 0.03% 583
2020
Q3 		$1.19M Buy
+10,000
New +$1.09M 0.03% 580
2019
Q3 		– Sell
-66,000
Closed -$6.92M – 819
2019
Q2 		$6.92M Buy
66,000
+11,100
+20% +$1.19M 0.35% 80
2019
Q1 		$6.88M Buy
+54,900
New +$6.82M 0.38% 72

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Caption Management's MDGL Position: Q4 2024 in Review

Caption Management sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2024, closing a stake of 12,300 shares — an estimated $3.46M sold.

Caption Management first reported a position in MDGL in Q3 2018 and held it in 9 quarters. The position peaked at $12.5M in Q1 2023. 283 funds tracked by Wall St. Rank hold MDGL as of Q4 2024.

  • Caption Management reported no remaining Madrigal Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Caption Management sold 12,300 Madrigal Pharmaceuticals shares in Q4 2024, an estimated $3.46M.
  • Caption Management first reported a position in Madrigal Pharmaceuticals in Q3 2018 and held it in 9 quarters.
  • Caption Management's Madrigal Pharmaceuticals position peaked at $12.5M in Q1 2023.
  • 283 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2024.

Based on Caption Management's 13F filing for Q4 2024, filed 14 Feb 2025.